Daicel Corporation (4202)

Name: Daicel Corporation (4202) — historial de estados financieros
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.

Basic Materials · Wall Street (EE. UU.) · Última actualización: 2026-10-02

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services.

Cifras clave

Capitalización bursátil: JPY 359 billion
Ingresos (ejercicio cerrado en 2026-03-31): JPY 579.6B
Beneficio neto: JPY 10.2B
Margen bruto: 25.2%
Margen neto: 1.8%

Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →

Cuenta de resultados anual

Cuenta de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Ingresos totales	JPY 579.6B	JPY 586.5B	JPY 558.1B	JPY 538.0B
Beneficio bruto	JPY 146.3B	JPY 164.7B	JPY 159.3B	JPY 145.8B
Ingresos operativos (EBIT)	JPY 42.1B	JPY 61.0B	JPY 62.4B	JPY 47.5B
Ingresos netos	JPY 10.2B	JPY 49.5B	JPY 55.8B	JPY 40.7B

Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.

Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de 4202. /companies/us/4202

Empresas similares

La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.

English version →Todas las acciones

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.